Table 2.
Tumor characteristics of men and women with hepatocellular carcinoma in Mexico, from 2015 to 2022 *.
| Female (n = 294) | Male (n = 403) | |||
|---|---|---|---|---|
| Missing, % | Missing, % | |||
| Differentiation | 41.5 | 44.4 | ||
| Well, % | 25.6 | 30.8 | ||
| Moderate, % | 36.0 | 35.7 | ||
| Poor to Undifferentiated, % | 12.2 | 16.5 | ||
| Not specified, % | 26.2 | 17.0 | ||
| Number of nodules | 0 | 0 | ||
| 1, % | 51 | 47.9 | ||
| 2–3, % | 23.1 | 19.6 | ||
| 4+, % | 7.5 | 14.9 | ||
| Not determined, % | 18.4 | 17.6 | ||
| Size of largest nodule, cm | 7.5(4.3) | 19.4 | 7.9(4.5) | 17.9 |
| Nodule > 5 cm, % | 77.6 | 0 | 77.9 | 0 |
| Satellite lesions, % | 17.0 | 2.4 | 19.1 | 3.2 |
| Extrahepatic disease, % | 24.5 | 2.7 | 24.3 | 4.2 |
| Metastasis | 0 | 0 | ||
| Yes, % | 19.4 | 19.9 | ||
| Not determined, % | 78.2 | 75.9 | ||
| BCLC | 11.2 | 12.2 | ||
| Early (0 or A) | 26.2 | 22.6 | ||
| Intermediate (B) | 24.8 | 20.8 | ||
| Advanced (C or D) | 37.8 | 44.4 | ||
| AFP at diagnosis, ng/mL | ||||
| <20, % | 29.3 | 29.0 | ||
| 20–399, % | 33.3 | 34.0 | ||
| 400+, % | 37.4 | 37.0 | ||
| Tumor type | 41.8 | 44.2 | ||
| Classic, % | 26.3 | 27.6 | ||
| Fibrolamellar, % | 4.7 | 1.8 | ||
| Clear cell, % | 1.8 | 3.1 | ||
| Other, % | 4.7 | 3.4 | ||
| Not determined, % | 62.6 | 64.0 |
* Values are mean (SD) for continuous variables and percentage (95% confidence interval) for categorical variables. The values of the categorical variables may not add up to 100% because of rounding. Abbreviations: Barcelona Clinic Liver Cancer (BCLC), alpha-fetoprotein (AFP).